About Geninus
Geninus is a publicly listed company based in Seoul (South Korea) founded in 2018. Genomic-based platform for disease prevention and cancer analysis is developed. Geninus has raised $13.33 million across 3 funding rounds from investors including KB Investment, Company K Partners and KTB Network. The company has 73 employees. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
Geninus was founded in 2018 in Seoul, South Korea, within the biotechnology sector focused on genomics. A disease prevention platform is developed, featuring the CancerScan test for mutation detection via next-generation sequencing of tumor DNA. Services provided include genomic analysis for target anticancer drugs, microbial community assessment for diet recommendations, single-cell cancer genome evaluation, and additional offerings such as LiquidSCAN, HealthSCAN, and comprehensive cancer tissue profiling.
- Headquarters Seoul, South Korea
- Employees 73
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website kr-geninus.com
- Legal Name Geninus, Inc.
- Annual Revenue$7.26 M (USD)62.4as on Dec 31, 2025
- Net Profit-$12.03 M (USD)-41.55as on Dec 31, 2025
- EBITDA-$5.84 M (USD)11.7as on Dec 31, 2025
- Total Equity Funding$13.33M (USD)
in 3 rounds
- Latest Funding Round$13.33M (USD), Series B
Aug 2020
- InvestorsKB Investment
& 4 more
- Employee Count73
Funding Insights of Geninus
Geninus has successfully raised a total of $13.33M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $13.33 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.33M
- Total Rounds 3
- Last Round Series B — $13.33M
- Investors Count 5
All 3 funding rounds of Geninus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $13.33M | Series B | – | IMM Investment, Company K Partners | – |
| Dec 2018 | Series A | – | – | – | |
| Oct 2018 | Angel Round | – | – | – |
5 investors in total: 5 institutional.
Investors in Geninus
Geninus has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include KB Investment, Company K Partners and KTB Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth stage companies are targeted for private equity investments. | imm.co.kr | Gangnam, South Korea | ||
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Stage & sector-agnostic VC firm funding companies in South Korea and the US | 1981 | ktbnetwork.com | Seongnam-si, South Korea | |
Early to growth stage PE and VC investments are conducted. | kipvc.com | Gangnam, South Korea |
Investor details for Geninus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Geninus
Geninus is a publicly listed company on the KRX with ticker symbol 389030 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2021
- Listed onKRX: 389030
- Listed entityGENINUS, Inc.
- Exchange sectorHealth technology
- ISINKR7389030008
- Share price1,741.00 KRW (+0.17% on the day) · 2026-10-14
- Market capitalisation68,463,763,756.00 KRW
- EPS (diluted, trailing year)-592.98 KRW
- Volume (last session)182,474
Financials of Geninus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 10.48B KRW | -17.37B KRW | -8.43B KRW |
| 2024 | 6.46B KRW | -12.27B KRW | -9.55B KRW |
| 2023 | 6.97B KRW | -9.68B KRW | -7.97B KRW |
| 2022 | 10.08B KRW | -9.38B KRW | -8.08B KRW |
| 2021 | 8.13B KRW | -9.02B KRW | -6.48B KRW |
Detailed financial statements for Geninus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Geninus
4 dated milestones of Geninus across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Geninus is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $13.3M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Geninus
The website of Geninus (kr-geninus.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▲ 30.2% vs previous month
Websites whose visitors overlap most with Geninus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biotimes.co.kr | 100% | #456,742 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Geninus
Complete news archive for Geninus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Geninus
Geninus was founded in 2018.
Geninus is headquartered in Seoul, South Korea.
Geninus is a funded company, having raised a total of $13.33M across 3 funding rounds to date.
Geninus has 73 employees.
Annual revenue of Geninus is $7.26M as on Dec 31, 2025.
Geninus was founded in 2018 in Seoul, South Korea, within the biotechnology sector focused on genomics. A disease prevention platform is developed, featuring the CancerScan test for mutation detection via next-generation sequencing of tumor DNA. Services provided include genomic analysis for target anticancer drugs, microbial community assessment for diet recommendations, single-cell cancer genome evaluation, and additional offerings such as LiquidSCAN, HealthSCAN, and comprehensive cancer tissue profiling.
Yes, Geninus is publicly traded on KRX under the ticker symbol 389030.
Geninus has 5 investors. Key investors include KB Investment, Company K Partners, KTB Network, IMM Korea, and KIPVC.